- Opinion
- [Reporter’s view] Confusion by 1+3 bill must be minimized
- by Lee, Tak-Sun Jun 30, 2021 05:56am
- Sharing the results of the biological equivalence test with other companies and obtaining permission is restricted by the revision of the law. The National Assembly passed the pharmaceutical affairs law amendment on the 29th, which included 1+3 bill. Accordingly, a trustee who manufactures medical supplies may share permitted data and sup
- Opinion
- [Reporter’s View] Fears cloud imminent RSA renewal
- by Eo, Yun-Ho Jun 14, 2021 05:56am
- With the Risk Sharing Agreement (RSA) contracts for major anticancer drugs soon to expire, stakeholders (government, pharmaceutical companies, patients) are faced with mixed concerns over the successful renewal of their RSA deals. In particular, the tension is tigher among pharmaceutical companies that have received or are planning to rec
- Opinion
- [Reporter's view] Tylenol is out of stock
- by Jun 2, 2021 06:10am
- As vaccinations began in earnest, the Tylenol crisis broke out in pharmacies. The Tylenol crisis has become inevitable as vaccinations for people aged 75 or older and those aged 65-74 have been implemented following preferential vaccinations for essential social workers. The government and the media are instructing people to take Tyleno
- Opinion
- [Reporter's View] It's up to pharmaceutical companies
- by An, Kyung-Jin May 17, 2021 05:53am
- Drug quality management is at stake. Over the past two months, four companies, including Binex, Vivozon, Chong Kun Dang and Hanall Biopharma, have been caught violating drug quality control. A total of 62 products are under administrative disposition due to violations of quality control by four companies. Including pharmaceutical companies in
- Opinion
- [FOCUS] Uncomfortable co-development regulation of medicines
- by Chon, Seung-Hyun May 11, 2021 05:59am
- There is a growing possibility that a bill will be implemented to regulate joint drug development by pharmaceutical companies. Recently, the National Assembly's Health and Welfare Committee held a bill subcommittee to pass a partial revision to the pharmaceutical practices law that limits the number of drugs that can be licensed through a sin
- Opinion
- [Reporter’s View] Support domestic COVID-19 vaccine first
- by May 10, 2021 05:56am
- The U.S had expressed support for waiving intellectual property (IP) protections for COVID-19 vaccines. Such support can induce the production of copies of Pfizer and Moderna’s COVID-19 vaccine, ultimately increasing vaccine supply. The U.S administration’s support was received with expectations, concerns, support as well as opposition.
- Opinion
- [Reporter’s View] Interest in the role and vision of GAs
- by Eo, Yun-Ho Apr 26, 2021 05:51am
- Multinational pharmaceutical companies have been eagerly hiring employees for Government Affairs (GA). Even companies that originally had no such position have newly created the position. Until now, the distinction between areas covered by Market Access (MA) and GA was unclear, and GA's target 'government institutions’ were limited to
- Opinion
- [Reporter's view]Controversy over Novavax vaccine
- by Lee, Tak-Sun Apr 16, 2021 06:02am
- The government explained that the Novavax COVID-19 vaccine, which had signed a technology transfer contract with SK Bioscience on the 12th, could be supplied as soon as possible in June. The release of this announcement raised controversy over the introduction of the Novavax vaccine, which has not yet been licensed abroad. Eventually, the
- Opinion
- [Reporter's view] Expensive vaccine sovereignty
- by Apr 15, 2021 05:56am
- The cervical cancer vaccine is Gardasil 9, and the rotavirus vaccines RotaTeq and Rotarix. Vaccines that are considered essential vaccinations, but consumers are less accessible. Foreign pharmaceutical companies are raising prices all at once. Gardasil 9 and RotaTeq's supply prices rose by 15% and 17%, respectively, from this month. RotaTeq
- Opinion
- [Reporter’s Eye] MNC CEOs' response to ‘Korea passing'
- by Eo, Yun-Ho Apr 5, 2021 05:52am
- MNC CEOs’ response to the ‘Korea passing’ phenomenon “Have you ever received pressure from corporate headquarters to consider ‘Korea passing’?” This question was asked to every multinational pharmaceutical company CEO interviewed by the reporter. Although the answer differed for each company and CEO, all the answers shared one
